Oppenheimer upgraded Ovid Therapeutics (OVID) to Outperform from Perform with a $4 price target The firm says OV329’s promise is “quite real” as a potential best-in-class next-generation GABA-AT ...
Regular MarketWatch readers might already be aware that U.S. stocks are historically expensive right now, based on several popular metrics. Some have argued that this could signal that the market has ...
Children who have had a stroke may be at higher risk for developing anxiety, depression and related physical symptoms such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback